AI-generated summary
The authors randomized 24 patients with STEMI undergoing primary PCI to laser therapy applied to the tibia bone or a sham control and reported no adverse effects. Troponin-T was lower after laser therapy than control, while door-to-balloon time and 9-month ejection fraction did not differ significantly, and the authors concluded the approach appears safe and feasible.
- Participants
- 24
- Who or what was studied
- Patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
- Limits stated in the abstract
- The study was small (12 patients per group), the primary objective was safety and feasibility, and several secondary differences were not statistically significant.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Primary outcome, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.